The dilutive offering will increase share count by ~22% (excluding warrants), likely pressuring RGNX shares near-term as the market absorbs supply. Monitor for use of proceeds toward pipeline programs (RGX-202, ABBV-RGX-314, NAVSUNLI) and any clinical updates that could offset dilution sentiment.
Price Chart
Executive Summary
REGENXBIO priced a public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant. Underwriters fully exercised their option for an additional 1,667,250 shares. Net proceeds are expected to be approximately $107.8 million. The offering closes July 20, 2026.
Key Facts
- Priced 10,003,889 shares at $9.00/share and 1,111,111 pre-funded warrants at $8.9999/warrant
- Underwriters exercised option in full for 1,667,250 additional shares
- Net proceeds expected to be approximately $107.8 million
- Pre-funded warrants have $0.0001 exercise price, exercisable at any time with no expiration
- Offering expected to close July 20, 2026
Financial Impact
Dilution of approximately 22% from new shares alone, plus potential dilution from 1,111,111 warrant shares; net proceeds of ~$107.8M added to cash position
Risk Factors
- Significant dilution to existing shareholders
- Potential overhang from pre-funded warrants exercisable at $0.0001
- Clinical-stage biotech with no approved products; capital needs may require further offerings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-308342 |
| Document: d40931dex41.htm | 0001193125-26-308342 |
| Document: d40931d8k.htm | 0001193125-26-308342 |
| Document: d40931dex51.htm | 0001193125-26-308342 |
| Document: d40931dex991.htm | 0001193125-26-308342 |
| Document: 0001193125-26-308342-index-headers.html | 0001193125-26-308342 |
| Document: 0001193125-26-308342-index.html | 0001193125-26-308342 |
| Document: 0001193125-26-308342.txt | 0001193125-26-308342 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.66 $7.47 | ▼ −22.67% | ▼ −22.93% | $7.43 (−23.08%) |
Aug 25, 2026 5w ago | 8-K | $9.38 $7.24 | ▼ −22.81% | ▼ −23.04% | $7.43 (−20.79%) |
Aug 6, 2026 8w ago | 8-K | $11.28 $9.20 | ▼ −18.44% | ▼ −19.04% | $7.43 (−34.13%) |
Aug 3, 2026 8w ago | Press Release | $9.96 $9.50 | ▼ −4.62% | ▼ −5.86% | $7.43 (−25.40%) |
Jul 20, 2026 10w ago | 8-K | $10.32 $11.33 | ▼ −9.79% | ▼ −5.67% | $7.43 (+28.00%) |
Jul 17, 2026 11w ago | Press Release | $9.89 $10.77 | ▼ −8.85% | ▼ −4.40% | $7.43 (+24.87%) |
Jun 29, 2026 13w ago | 8-K | $11.83 $9.73 | ▼ −17.75% | ▼ −17.47% | $7.43 (−37.19%) |
Jun 3, 2026 17w ago | 8-K | $6.69 $13.28 | ▲ +98.51% | ▲ +99.51% | $7.43 (+11.06%) |
May 14, 2026 20w ago | 8-K | $6.25 $6.66 | ▲ +6.65% | ▲ +7.50% | $7.43 (+18.98%) |
Mar 5, 2026 30w ago | 8-K | $8.72 $8.53 | ▼ −2.18% | ▲ +1.61% | $7.43 (−14.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access